登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Science Advances，10月20日，Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-11-16

  • Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate

    View ORCID ProfileSandhya Bangaru1, View ORCID ProfileGabriel Ozorowski1, Hannah L. Turner1, View ORCID ProfileAleksandar Antanasijevic1, View ORCID ProfileDeli Huang2, View ORCID ProfileXiaoning...

    Science 20 Oct 2020:

    eabe1502

    DOI: 10.1126/science.abe1502

    Abstract

    Vaccine efforts against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the current COVID-19 pandemic are focused on SARS-CoV-2 spike glycoprotein, the primary target for neutralizing antibodies. We performed cryo-EM and site-specific glycan analysis of one of the leading subunit vaccine candidates from Novavax based on a full-length spike protein formulated in polysorbate 80 (PS 80) detergent. Our studies reveal a stable prefusion conformation of the spike immunogen with slight differences in the S1 subunit compared to published spike ectodomain structures. We also observed novel interactions between the spike trimers allowing formation of higher order spike complexes. This study confirms the structural integrity of the full-length spike protein immunogen and provides a basis for interpreting immune responses to this multivalent nanoparticle immunogen.

  • 原文来源：https://science.sciencemag.org/content/early/2020/10/19/science.abe1502
83浏览量
原文链接
相关报告

  • 《Science，3月27日，Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-27
    • Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 Renhong Yan1,2, Yuanyuan Zhang1,2,*, Yaning Li3,*, Lu Xia1,2, Yingying Guo1,2, Qiang Zhou1,2,† See all authors and affiliations Science 27 Mar 2020: Vol. 367, Issue 6485, pp. 1444-1448 DOI: 10.1126/science.abb2762 Abstract Angiotensin-converting enzyme 2 (ACE2) is the cellular receptor for severe acute respiratory syndrome–coronavirus (SARS-CoV) and the new coronavirus (SARS-CoV-2) that is causing the serious coronavirus disease 2019 (COVID-19) epidemic. Here, we present cryo–electron microscopy structures of full-length human ACE2 in the presence of the neutral amino acid transporter B0AT1 with or without the receptor binding domain (RBD) of the surface spike glycoprotein (S protein) of SARS-CoV-2, both at an overall resolution of 2.9 angstroms, with a local resolution of 3.5 angstroms at the ACE2-RBD interface. The ACE2-B0AT1 complex is assembled as a dimer of heterodimers, with the collectrin-like domain of ACE2 mediating homodimerization. The RBD is recognized by the extracellular peptidase domain of ACE2 mainly through polar residues. These findings provide important insights into the molecular basis for coronavirus recognition and infection.
    128浏览量
    原文链接

  • 《bioRxiv，6月27日，Modified Vaccinia Ankara Based SARS-CoV-2 Vaccine Expressing Full-Length Spike Induces Strong Neutralizing Antibody Response》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-06-29
    • Modified Vaccinia Ankara Based SARS-CoV-2 Vaccine Expressing Full-Length Spike Induces Strong Neutralizing Antibody Response View ORCID ProfileNanda Kishore Routhu,  View ORCID ProfileSailaja Gangadhara,  View ORCID ProfileNarayanaiah Cheedarla, Ayalnesh Shiferaw,  View ORCID ProfileSheikh Abdul Rahman, Anusmita Sahoo, Pei-Yong Shi,  View ORCID ProfileVineet D Menachery, Katharine Floyd,  View ORCID ProfileStephanie Fischinger,  View ORCID ProfileCaroline Atyeo,  View ORCID ProfileGalit Alter,  View ORCID ProfileMehul S Suthar,  View ORCID ProfileRama Rao Amara doi: https://doi.org/10.1101/2020.06.27.175166 Abstract There is a great need for the development of vaccines for preventing SARS-CoV-2 infection and mitigating the COVID-19 pandemic. Here, we developed two modified vaccinia Ankara (MVA) based vaccines which express either a membrane anchored full-length spike protein (MVA/S) stabilized in a prefusion state or the S1 region of the spike (MVA/S1) which forms trimers and is secreted. Both immunogens contained the receptor-binding domain (RBD) which is a known target of antibody-mediated neutralization. Following immunizations with MVA/S or MVA/S1, both spike protein recombinants induced strong IgG antibodies to purified full-length SARS-CoV-2 spike protein. The MVA/S induced a robust antibody response to purified RBD, S1 and S2 whereas MVA/S1 induced an antibody response to the S1 region outside of the RBD region. Both vaccines induced an antibody response in the lung and that was associated with induction of bronchus-associated lymphoid tissue. MVA/S but not MVA/S1 vaccinated mice generated robust neutralizing antibody responses against SARS-CoV-2 that strongly correlated with RBD antibody binding titers. Mechanistically, S1 binding to ACE-2 was strong but reduced following prolonged pre-incubation at room temperature suggesting confirmation changes in RBD with time. These results demonstrate MVA/S is a potential vaccine candidate against SARS-CoV-2 infection.
    51浏览量
    原文链接